Work

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure

Year: 2008

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-008-9187-3

Authors: R. Dreicer, W. M. Stadler, F. R. Ahmann, T. Whiteside, N. Bizouarne, B. Acres, J.-M. Limacher, P. Squiban, A. Pantuck

Institutions: Cleveland Clinic, University of Chicago, University of Arizona Cancer Center, UPMC Hillman Cancer Center, Transgene (France), University of California, Los Angeles, Ronald Reagan UCLA Medical Center, UCLA Medical Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1966617868

FWCI: 5.282

Cites: 26

Cited by: 79

Related to: 10